73
Participants
Start Date
November 30, 2007
Primary Completion Date
April 30, 2010
Study Completion Date
June 30, 2010
AS902330
3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
Placebo
Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
"UMHAT Sv. Ivan Rilski, Clinical Research Unit for Phase I", Sofia
Frederiksberg Hospital, Frederiksberg
Gentofte Hospital, Hellerup
Nordsjællands Hospital - Hørsholm, Hørsholm
Silkeborg sygehus, Silkeborg
Regionshospitalet Viborg, Viborg
Kuopio University Hospital, Kuopio
Oulu University Hospital, Oulu
Turku University Central Hospital, Turku
FARMOVS-PAREXEL (Pty) Ltd, University of the Free State, Bloemfontein
PAREXEL-George, George
PAREXEL-Port Elizabeth, Mercantile Hospital, Port Elizabeth
Sahlgrenska University Hospital/Östra, Gothenburg
Hässleholms Sjukhus, Hässleholm
Kungälv Sjukhus, Kungälv
Lund University Hospital, Lund
Malmö University Hospital, Malmo
Danderyds Sjukhus, Stockholm
Cambridge University Hospitals, Cambridge
Merck Serono S.A., Geneva
INDUSTRY
Merck KGaA, Darmstadt, Germany
INDUSTRY